41 companies

CSL

Market Cap: AU$73.8b

Engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.

CSL

AU$153.27

7D

2.2%

1Y

-40.7%

Mesoblast

Market Cap: AU$3.1b

Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.

MSB

AU$2.41

7D

1.3%

1Y

-9.4%

Neuren Pharmaceuticals

Market Cap: AU$1.7b

A biopharmaceutical company, develops drugs for the treatment of neurological disorders.

NEU

AU$13.07

7D

2.5%

1Y

-1.5%

Clinuvel Pharmaceuticals

Market Cap: AU$585.8m

A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.

CUV

AU$11.67

7D

10.1%

1Y

3.5%

Immutep

Market Cap: AU$582.1m

A biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia.

IMM

AU$0.40

7D

8.2%

1Y

29.5%

Dimerix

Market Cap: AU$285.2m

A biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia.

DXB

AU$0.47

7D

0%

1Y

-1.0%

Orthocell

Market Cap: AU$249.6m

A regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally.

OCC

AU$0.92

7D

0%

1Y

-34.8%

Aroa Biosurgery

Market Cap: AU$241.8m

Develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally.

ARX

AU$0.70

7D

-0.7%

1Y

21.7%

Mayne Pharma Group

Market Cap: AU$215.3m

A specialty pharmaceutical company, focuses on the commercialization of women’s health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.

MYX

AU$2.65

7D

1.1%

1Y

-63.2%

Starpharma Holdings

Market Cap: AU$210.0m

A biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally.

New

SPL

AU$0.50

7D

2.0%

1Y

334.8%

Vita Life Sciences

Market Cap: AU$141.5m

A healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China.

VLS

AU$2.55

7D

-1.9%

1Y

57.4%

Paradigm Biopharmaceuticals

Market Cap: AU$123.0m

Engages in the research and development of therapeutic products for human use in Australia.

PAR

AU$0.28

7D

-6.7%

1Y

-54.5%

Botanix Pharmaceuticals

Market Cap: AU$118.2m

Operates as a commercial dermatology company in Australia and the United States.

BOT

AU$0.06

7D

-46.7%

1Y

-88.3%

Island Pharmaceuticals

Market Cap: AU$109.1m

A drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America.

ILA

AU$0.37

7D

-3.9%

1Y

174.1%

Bioxyne

Market Cap: AU$100.8m

Manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czechia, Switzerland, France, Germany, and Japan.

BXN

AU$0.045

7D

-6.3%

1Y

18.4%

Trajan Group Holdings

Market Cap: AU$94.6m

Develops, manufactures, and sells analytical and life science products and devices in Malaysia, Japan, Australia, New Zealand, the United States, Europe, the Middle East, Africa, and India.

TRJ

AU$0.62

7D

-3.9%

1Y

-22.5%

LTR Pharma

Market Cap: AU$88.2m

A clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia.

LTP

AU$0.48

7D

-5.8%

1Y

-26.0%

Alterity Therapeutics

Market Cap: AU$87.0m

Engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia.

ATH

AU$0.008

7D

0%

1Y

-27.3%

Radiopharm Theranostics

Market Cap: AU$78.0m

A clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs.

RAD

AU$0.022

7D

0%

1Y

-8.3%

Amplia Therapeutics

Market Cap: AU$64.1m

A clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia.

ATX

AU$0.13

7D

0%

1Y

52.4%

Syntara

Market Cap: AU$55.5m

Operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia.

SNT

AU$0.034

7D

6.3%

1Y

-60.0%

Medical Developments International

Market Cap: AU$52.9m

Manufactures and distributes emergency medical solutions in Australia, Asia, Europe, the United States, and internationally.

MVP

AU$0.47

7D

3.3%

1Y

-40.9%

NeuroScientific Biopharmaceuticals

Market Cap: AU$38.2m

Engages in the research and development of biomedical products targeting neurodegenerative conditions.

NSB

AU$0.12

7D

-11.5%

1Y

210.8%

Little Green Pharma

Market Cap: AU$35.1m

Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.

LGP

AU$0.12

7D

-4.2%

1Y

-14.8%

Avecho Biotechnology

Market Cap: AU$34.9m

A biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, the Americas, and India.

AVE

AU$0.0095

7D

5.6%

1Y

58.3%

Vitura Health

Market Cap: AU$33.1m

Engages in the sale and distribution of medicinal cannabis products in Australia.

VIT

AU$0.05

7D

-9.1%

1Y

-52.4%

Genetic Signatures

Market Cap: AU$27.3m

Operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas.

GSS

AU$0.12

7D

-7.7%

1Y

-75.8%

IDT Australia

Market Cap: AU$21.4m

Engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and finished dose forms (FDF) products in Australia, Asia, Europe, and the United States.

IDT

AU$0.05

7D

4.2%

1Y

-54.5%

Noxopharm

Market Cap: AU$21.3m

A biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia.

NOX

AU$0.073

7D

-2.7%

1Y

-9.9%

Peak Processing

Market Cap: AU$19.7m

Manufactures, distributes, and sells recreational cannabis products in Canada and the United States.

PKP

AU$0.017

7D

6.3%

1Y

-26.1%

Cann Group

Market Cap: AU$11.1m

Engages in the breeding, cultivation, manufacture, and sale of medicinal cannabis in Australia and Europe.

CAN

AU$0.007

7D

-12.5%

1Y

-76.7%

Chimeric Therapeutics

Market Cap: AU$11.0m

A clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia.

CHM

AU$0.0025

7D

25.0%

1Y

-68.8%

ECS Botanics Holdings

Market Cap: AU$9.6m

Engages in the cultivation, manufacture, and sale of medicinal cannabis products in Australia and internationally.

ECS

AU$0.006

7D

9.1%

1Y

-58.6%

Biotron

Market Cap: AU$9.5m

A biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia.

BIT

AU$0.0035

7D

16.7%

1Y

-56.3%

Immuron

Market Cap: AU$9.4m

A biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada.

IMC

AU$0.029

7D

3.6%

1Y

-62.8%

Percheron Therapeutics

Market Cap: AU$7.6m

Engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia.

PER

AU$0.007

7D

-12.5%

1Y

-46.2%

Page 1 of 2